CONMED Corporation
CONMED Corporation (CNMD) Financial Performance & Income Statement Overview
Explore the financials of CONMED Corporation (CNMD), including yearly and quarterly data on income, cash flow, and balance sheets.
CONMED Corporation (CNMD) Income Statement & Financial Overview
Review CONMED Corporation CNMD income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $321.26M | $347.93M | $316.70M | $330.75M |
| Cost of Revenue | $143.50M | $147.60M | $137.71M | $157.59M |
| Gross Profit | $177.75M | $200.33M | $179.00M | $173.15M |
| Gross Profit Ratio | $0.55 | $0.58 | $0.57 | $0.52 |
| R&D Expenses | $12.95M | $13.18M | $13.56M | $14.10M |
| SG&A Expenses | $148.85M | $132.67M | $99.73M | $121.84M |
| Operating Expenses | $161.79M | $145.84M | $113.29M | $135.94M |
| Total Costs & Expenses | $305.30M | $293.44M | $250.99M | $293.54M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $8.29M | $8.86M | $9.25M | $9.59M |
| Depreciation & Amortization | $0.00 | $18.006M | $17.97M | $12.77M |
| EBITDA | $34.21M | $70.50M | $83.68M | $47.11M |
| EBITDA Ratio | $0.11 | $0.20 | $0.26 | $0.14 |
| Operating Income | $15.96M | $52.50M | $65.71M | $37.21M |
| Operating Income Ratio | $0.05 | $0.15 | $0.21 | $0.11 |
| Other Income/Expenses (Net) | -$8.29M | -$8.86M | -$9.25M | -$9.59M |
| Income Before Tax | $7.67M | $43.64M | $56.45M | $37.51M |
| Income Before Tax Ratio | $0.02 | $0.13 | $0.18 | $0.11 |
| Income Tax Expense | $1.64M | $9.89M | $7.47M | $7.54M |
| Net Income | $6.04M | $33.76M | $48.98M | $29.98M |
| Net Income Ratio | $0.02 | $0.10 | $0.15 | $0.09 |
| EPS | $0.19 | $1.09 | $1.59 | $0.97 |
| Diluted EPS | $0.19 | $1.08 | $1.57 | $0.96 |
| Weighted Avg Shares Outstanding | $30.97M | $30.85M | $30.86M | $30.81M |
| Weighted Avg Shares Outstanding (Diluted) | $31.15M | $31.11M | $31.11M | $31.11M |
Over the last four quarters, CONMED Corporation achieved steady financial progress, growing revenue from $330.75M in Q2 2024 to $321.26M in Q1 2025. Gross profit stayed firm with margins at 55% in Q1 2025 versus 52% in Q2 2024. Operating income totaled $15.96M in Q1 2025, maintaining a 5% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $34.21M. Net income dropped to $6.04M, with EPS at $0.19. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan